T1	Participants 47 100	hemodialysis patients during growth hormone treatment
T2	Participants 114 161	Adult patients with chronic renal failure (CRF)
T3	Participants 173 304	symptoms as fatigue, wasting, and reduced working capacity with concomitant findings of reduced cardiac performance and muscle mass
T4	Participants 345 426	imbalance in the somatostatin/somatomedine axis resulting in increased catabolism
T5	Participants 646 686	20 adult enfeebled hemodialysis patients
